S&P Futures
4,134.75+7.00(+0.17%)Dow Futures
33,713.00+4.00(+0.01%)Nasdaq Futures
13,776.00+25.75(+0.19%)
Aurinia Pharmaceuticals Inc. (AUPH)
12.55 -0.07 (-0.55%)
Pre-Market: 8:08AM EDT
Chart Events
Performance Outlook
| Previous Close | 12.45 |
| Open | 12.52 |
| Bid | 12.63 x 1100 |
| Ask | 12.80 x 1000 |
| Day's Range | 12.26 - 12.81 |
| 52 Week Range | 11.60 - 20.50 |
| Volume | 2,701,062 |
| Avg. Volume | 4,123,781 |
| Market Cap | 1.572B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | May 12, 2021 - May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
Fair Value
Related Research
- Business Wire
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.
- Benzinga
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at the National Kidney Foundation 2021 Spring Clinical Meeting. Pooled data from the AURA-LV and AURORA 1 study demonstrate that Lupkynis, combined with mycophenolate mofetil (MMF) and low-dose corticosteroids, led to treatment benefits across biopsy class subgroups compared with MMF and low-dose corticosteroids alone (placebo). MMF and low-dose corticosteroids are considered standard of care for the treatment of LN. In January this year, the FDA approved Lupkynis combined with a background immunosuppressive therapy regimen to treat adult patients with active LN. Data from 532 patients from the AURA-LV and AURORA 1 studies were integrated into a post-hoc analysis of complete renal response (CRR) by LN biopsy class. The odds ratios (OR) for CRR for Lupkynis versus placebo were 4.26 for pure Class III, 2.59 for pure Class IV, 1.5 for pure Class V, and 2.68 for mixed Class III/IV/V patients. Achieving 1 or greater indicates that Lupkynis is favored over placebo. Additional efficacy data demonstrated the potential to improve renal response regardless of disease progression at diagnosis. Price Action: AUPH shares are trading 1.9% higher at $12.9 in premarket trading on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaGlobal Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of TreatmentStrongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Business Wire
Aurinia Presents Data Demonstrating LUPKYNISâ„¢ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., M.P.H., Founder and Director of Columbia University Irving Medical Center’s Lupus Center and the Director of Rheumatology Clinical Trials.
